WallStSmart

Enanta Pharmaceuticals Inc (ENTA)vsModerna Inc (MRNA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Moderna Inc generates 3314% more annual revenue ($2.23B vs $65.26M). ENTA leads profitability with a -96.9% profit margin vs -141.4%. MRNA earns a higher WallStSmart Score of 21/100 (F).

ENTA

Avoid

21

out of 100

Grade: F

Growth: 2.0Profit: 2.0Value: 6.7Quality: 5.5
Piotroski: 3/9Altman Z: -1.83

MRNA

Avoid

21

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 6.7Quality: 7.5
Piotroski: 3/9Altman Z: 2.09
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ENTAUndervalued (+36.6%)

Margin of Safety

+36.6%

Fair Value

$22.49

Current Price

$12.96

$9.53 discount

UndervaluedFair: $22.49Overvalued
MRNAUndervalued (+70.0%)

Margin of Safety

+70.0%

Fair Value

$134.97

Current Price

$143.97

$9.00 discount

UndervaluedFair: $134.97Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ENTA0 strengths · Avg: 0/10

No standout strengths identified

MRNA2 strengths · Avg: 9.0/10
Market CapQuality
$56.02B9/10

Large-cap with strong market position

Debt/EquityHealth
0.199/10

Conservative balance sheet, low leverage

Areas to Watch

ENTA4 concerns · Avg: 2.5/10
Market CapQuality
$388.24M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-53.2%2/10

ROE of -53.2% — below average capital efficiency

Revenue GrowthGrowth
-21.6%2/10

Revenue declined 21.6%

MRNA4 concerns · Avg: 3.3/10
Price/BookValuation
8.5x4/10

Trading at 8.5x book value

Revenue GrowthGrowth
2.1%4/10

2.1% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-46.6%2/10

ROE of -46.6% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : ENTA

ENTA has a balanced fundamental profile.

Bull Case : MRNA

The strongest argument for MRNA centers on Market Cap, Debt/Equity.

Bear Case : ENTA

The primary concerns for ENTA are Market Cap, Piotroski F-Score, Return on Equity.

Bear Case : MRNA

The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.

Key Dynamics to Monitor

MRNA carries more volatility with a beta of 1.11 — expect wider price swings.

MRNA is growing revenue faster at 2.1% — sustainability is the question.

ENTA generates stronger free cash flow (-10M), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ENTA scores higher overall (21/100 vs 21/100). MRNA offers better value entry with a 70.0% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Enanta Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company is headquartered in Watertown, Massachusetts.

Moderna Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.

Want to dig deeper into these stocks?